LONDON–(BUSINESS WIRE)–The global hirsutism treatment market is poised to grow by USD 2.23 billion during 2019-2023, progressing at a CAGR of almost 14% during the forecast period. Request Free Sample Pages
Read the 118-page research report with TOC on “Hirsutism Treatment Market Analysis Report by Type (medications and procedures), by Geography (North America, Europe, Asia, and ROW), and Segment Forecasts, 2019 – 2023”
The increase in associated risk factors drives the market. Also, the popularity of off-label genetic drugs is anticipated to boost the growth of the hirsutism treatment market further.
There is a surge noticed in androgen-related disorders due to the adoption of poor lifestyle habits and the rapid onset of modernization. PCOS is one such androgen disorder associated with menstrual irregularities. About three-fourths of women with PCOS have hirsutism due to the high secretion of androgen. Hirsutism can also be caused as an adverse effect of certain medications, including androgen therapy that includes testosterone, dehydroepiandrosterone (DHEA), and the drug, danazol, which are used to treat osteoporosis, and endometriosis. Therefore, a rise in the cases of associated risk factors will lead to an increase in hirsutism, which will propel the demand for hirsutism treatment options.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Hirsutism Treatment Market Companies:
ALLERGAN owns and operates businesses under various segments such as US specialized therapeutics, US general medicine, and international and others. The product offered by the company is VANIQA. It is a cream containing 13.9% of anhydrous eflornithine hydrochloride as eflornithine hydrochloride monohydrate (150 mg/g). It is indicated for the reduction of unwanted facial hair in women.
Bayer AG operates the business under four segments, which include pharmaceuticals, consumer health, crop science, and animal health. The company’s key offerings include ANDROCUR, ANGELIQ, and NATAZIA.
Lumenis has business operations under the medical devices segment. The product offered by the company is SPLENDOR X. It is a solid-state laser system equipped with the unique BLEND X technology for fast and effective hair removal.
Merck & Co., Inc.
Merck & Co., Inc. operates business under three segments, which include pharmaceutical, animal health, and others. The company’s key offerings include EULEXIN and PROPECIA.
Pfizer Inc. operates the business through the following segments: innovative health and essential health. The company’s key offerings in the hirsutism treatment market include ALDACTAZIDE and ALDACTONE.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Hirsutism Treatment Type Outlook (Revenue, USD Million, 2019 – 2023)
Hirsutism Treatment Regional Outlook (Revenue, USD Million, 2019 – 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.